Skip to main content
. 2023 Jul 17;8(4):101608. doi: 10.1016/j.esmoop.2023.101608

Table 2.

List of active and recruiting clinical trials investigating T-DXd in advanced breast cancer, as of 22 October 2022

CT full name CT name CT code CT phase Patients HER2
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2+ BC DESTINY-Breast12 NCT04739761 Phase III 500 POS
A Study of Tucatinib Plus T-DXd in HER2+ BC HER2CLIMB-04 NCT04539938 Phase II 70 POS
Study of T-DXd versus Investigator's Choice Chemotherapy in HER2-low, HR+, Metastatic BC DESTINY-Breast06 NCT04494425 Phase III 850 Low
T-DXd With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2+ Metastatic BC DESTINY-Breast09 NCT04784715 Phase III 1134 POS
A Phase 1b/2 Study of T-DXd Combinations in HER2+ Metastatic BC DESTINY-Breast07 NCT04538742 Phase I/II 450 POS
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic BC DESTINY-Breast08 NCT04556773 Phase I 182 Low
T-DXd and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer NCT04042701 Phase I 115 Both
Testing the Biological Effects of T-DXd on Patients With Advanced Cancer NCT04294628 Phase I 37 Both
Testing the Combination of Two Anti-cancer Drugs, T-DXd and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene DASH NCT04704661 Phase I 15 POS
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies PETRA NCT04644068 Phase I/II 715 NEG

ABC, advanced breast cancer; BC, breast cancer; CT, clinical trial; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NEG, negative; POS, positive; T-DXd, trastuzumab deruxtecan.